Wealth Enhancement Advisory Services LLC increased its holdings in shares of Cencora, Inc. (NYSE:COR – Free Report) by 3.2% in the third quarter, Holdings Channel reports. The firm owned 277,077 shares of the company’s stock after acquiring an additional 8,636 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Cencora were worth $62,364,000 as of its most recent SEC filing.
Other large investors have also recently added to or reduced their stakes in the company. New Millennium Group LLC purchased a new stake in shares of Cencora in the second quarter worth about $26,000. TCTC Holdings LLC acquired a new stake in Cencora in the first quarter valued at approximately $29,000. TFO Wealth Partners LLC acquired a new stake in Cencora in the first quarter valued at approximately $30,000. LRI Investments LLC acquired a new position in shares of Cencora during the first quarter worth $31,000. Finally, MFA Wealth Advisors LLC purchased a new position in shares of Cencora in the second quarter valued at $30,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of Cencora stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the completion of the transaction, the insider now directly owns 19,980,000 shares in the company, valued at $4,806,388,800. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the sale, the insider now directly owns 19,980,000 shares of the company’s stock, valued at $4,806,388,800. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the transaction, the chairman now directly owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 4,461,153 shares of company stock worth $1,073,075,720 over the last quarter. 15.80% of the stock is owned by company insiders.
Analysts Set New Price Targets
Get Our Latest Analysis on Cencora
Cencora Trading Down 0.3 %
NYSE:COR opened at $234.47 on Friday. The company has a market cap of $46.77 billion, a PE ratio of 25.65, a P/E/G ratio of 1.40 and a beta of 0.44. The business’s 50 day moving average is $232.15 and its two-hundred day moving average is $230.81. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. Cencora, Inc. has a 52 week low of $182.75 and a 52 week high of $247.66.
Cencora (NYSE:COR – Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The firm had revenue of $74.20 billion for the quarter, compared to analysts’ expectations of $73.32 billion. During the same period last year, the business posted $2.92 earnings per share. The firm’s revenue for the quarter was up 10.8% on a year-over-year basis. On average, analysts predict that Cencora, Inc. will post 13.63 EPS for the current year.
Cencora Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were given a dividend of $0.51 per share. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date was Friday, August 9th. Cencora’s dividend payout ratio is presently 22.32%.
Cencora Company Profile
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
See Also
- Five stocks we like better than Cencora
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- How to buy stock: A step-by-step guide for beginnersÂ
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Most active stocks: Dollar volume vs share volume
- MarketBeat Week in Review – 10/21- 10/25
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.